Is NCT05969860 recruiting in Grand Forks, ND?

Yes, NCT05969860 is currently recruiting participants at its Grand Forks, ND location. This advanced cancer clinical trial is actively enrolling qualified participants.

How do I join the advanced cancer clinical trial in Grand Forks?

To join this clinical trial in Grand Forks, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Grand Forks clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Cancer Clinical Trial in Grand Forks, ND

About This Advanced Cancer Study in Grand Forks

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Female or male patients with histologically confirmed malignancy. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required.

Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines.

Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Patients may receive any combination of any above listed medications or regimens:

Eligible disease cancer types:

Anal cancer

Appendiceal carcinoma

Basal cell carcinoma

Bladder cancer

Biliary cancer

Breast cancer

Central Nervous System malignancy including glioblastoma

Cervical cancer

Cholangiocarcinoma

Colorectal carcinoma

Endometrial cancer

Fallopian tube cancer

Gastroesophageal cancer \[including gastric, esophageal, and gastroesophageal junction (GEJ) cancers\]

Germ cell carcinoma

Head and Neck cancer

Hepatocellular Carcinoma

Merkel Cell

Multiple Myeloma

Myelodysplastic syndrome

Myeloid Disorders

Neuroendocrine carcinoma

Ovarian cancer

Pancreatic adenocarcinoma

Penile carcinoma

Peritoneal carcinoma

Prostate cancer

Renal cell cancer

Squamous cell Carcinoma of the Skin

Testicular cancer

Urethral carcinoma

Vaginal carcinoma

Vulvar carcinoma

Eligible Regimens

Fluorouracil (5-FU) +/- leucovorin +/- bevacizumab +/- trastuzumab

5FU +/- leucovorin +/- bevacizumab +/- nivolumab

Atezolizumab +/- bevacizumab

Atezolizumab +/- bevacizumab + cobimetinib, atezolizumab +/- bevacizumab + vemurafenib, atezolizumab +/- bevacizumab + cobimetinib + vemurafenib

Avelumab + axitinib

Bevacizumab

Bevacizumab + capecitabine

Bevacizumab + irinotecan (+/- capecitabine)

Bevacizumab + olaparib, bevacizumab + lenvatinib, bevacizumab + niraparib, bevacizumab + rucaparib

Bevacizumab + Temozolomide, Bevacizumab + Lomustine, or Bevacizumab + everolimus

Bevacizumab + trifluridine/tipiracil

Bortezomib + cyclophosphamide, bortezomib + lenalidomide, bortezomib + pomalidomide, bortezomib + selinexor

Bortezomib + venetoclax

Carfilzomib

Carfilzomib + cyclophosphamide, carfilzomib + lenalidomide, carfilzomib + pomalidomide, carfilzomib + selinexor

Carfilzomib + venetoclax

Cisplatin/5-FU

Cisplatin/etoposide

Cisplatin + durvalumab

Cisplatin + gemcitabine

Cisplatin + gemcitabine + durvalumab

Daratumumab (+ oral \[PO\] cyclophosphamide, lenalidomide, pomalidomide, or selinexor)

Daratumumab + bortezomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)

Daratumumab + carfilzomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)

Durvalumab + tremelimumab

FOLFIRI +/- bevacizumab (5FU +/- leucovorin + irinotecan)

Fam-trastuzumab deruxtecan

Fulvestrant

Fulvestrant + ribociclib, fulvestrant + abemaciclib, fulvestrant + palbociclib, fulvestrant + alpelisib, or fulvestrant + capivasertib

Gemcitabine

Gemcitabine + durvalumab

Gemcitabine + paclitaxel protein-bound

Goserelin acetate

Irinotecan + capecitabine

Nivolumab + cabozantinib

Nivolumab-relatlimab

Pembrolizumab

Pembrolizumab + axitinib, pembrolizumab + lenvatinib, pembrolizumab + capecitabine, pembrolizumab + dabrafenib +/- trametinib, pembrolizumab + trametinib)

Pemetrexed + pembrolizumab

Trastuzumab + paclitaxel

Trastuzumab with or without pertuzumab maintenance (SQ or IV) (+/- tucatinib +/- capecitabine)

These regimens can be used only if patients are receiving one of the regimens above:

Darbepoetin-alfa

Note: Female or male patients with histologically confirmed malignancy who are currently receiving treatment with one of the above eligible regimens may receive supportive care medications for treatment or prevention of bone metastases, including agents such as:

Zoledronic acid

Patient has had adequate tolerability of their clinical standard of care cancer treatment in the opinion of their treating physician and no drug-related infusion reactions prior to consent

Patients who according to documentation from their treating provider plan to continue the treatment regimen they are currently prescribed for at least 24 weeks from the start of cycle following randomization.

Residing within the area serviced by supplier and paramedic network

Residence has wireless fidelity (wifi) to enable a reliable connection with the remote Command Center or it is suitable for connection through a wireless network solution

Age \>= 18 years at time of registration

Signed informed consent form by patient

Willing and able to comply with the study protocol in the investigator's judgement

Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2

Ability to complete questionnaire(s) by themselves or with assistance

RANDOMIZATION ELIGIBILITY CRITERIA: In addition to the criteria above, confirmation by the CCBW Command Center that the patient has adequate tolerability to the standard of care cancer therapy and no drug-related infusion reactions since pre-registration and prior to registration

Exclusion Criteria

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm. Note: Patients are permitted concomitant standard of care oral drugs such as ribociclib, abemaciclib, or palbociclib in combination with endocrine therapy (e.g., Leuprolide, fulvestrant intramuscular \[IM\], etc.); tucatinib and capecitabine in combination with trastuzumab and pertuzumab for HER2 positive breast cancer; dexamethasone, cyclophosphamide, lenalidomide or pomalidomide for multiple myeloma; temozolomide, lomustine, or afinitor in combination with avastin for glioblastoma. In addition, all oral anti-hormonal agents for breast and prostate cancer are permitted (e.g., tamoxifen, arimidex, abiraterone, etc.) if used in combination with any of the drugs

Requiring 24/7 assistance with activities of daily living (ADLs)

Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection

Symptomatic congestive heart failure

Unstable angina pectoris

Cardiac arrhythmia

Myocardial infarction =\< 6 months

Wound healing disorder

Or psychiatric illness/social situations that would limit compliance with study requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Forks?

Yes, this clinical trial (NCT05969860) has an active research site in Grand Forks, ND that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Cancer Treatment Options in Grand Forks, ND

If you're searching for advanced cancer treatment options in Grand Forks, ND, this clinical trial (NCT05969860) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Forks research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced advanced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced cancer clinical trials near you to find additional studies recruiting in your area.

Advanced Cancer Clinical Trial in Grand Forks, ND

Expert Care in Grand Forks

IRB Approved

No-Cost Care

Apply for This Grand Forks Location

Why Participate?

Simple Process